Skip to main content
Top
Published in:

Open Access 16-01-2024 | Liver Cirrhosis | IM - ORIGINAL

Electronic sanitary database: a new potential tool to identify occult chronic liver disease in general population

Authors: Silvia Cagnin, Andrea Martini, Daniele Donato, Paolo Angeli, Patrizia Pontisso

Published in: Internal and Emergency Medicine | Issue 3/2024

Login to get access

Abstract

Chronic liver disease (CLD) is a leading global cause of mortality, morbidity, and healthcare resource utilization. However, the burden of CLD is underestimated because the course of the disease is often asymptomatic until clinical decompensation and the development of life-threatening complications. In this study, we assessed the use of available blood tests from electronic medical records for identifying individuals with undiagnosed CLD in the general population. We analyzed a total of 202,529 blood tests obtained from 99,848 adults recorded in the Electronic Health Records of the Padova Teaching Hospital. Transaminases levels > 1.5 times the normal value indicated occult CLD, while platelet counts < 120,000/μL identified occult cirrhosis. We characterized patients using Italian Medical Exemptions (IME), excluding oncologic cases. Overt and occult cirrhosis prevalence was 1% and 4.18%, respectively, while overt and occult CLD affected 2.85% and 4.61% of the population. The epidemiology of patients with overt and occult cirrhosis was similar but significantly different from that of the controls. Among subjects aged 60–70 years, working disability was twofold higher in those with occult cirrhosis compared to those with overt cirrhosis. Occult CLD and cirrhosis had higher prevalence rates than diagnosed cases in the general population. Electronic medical record data may serve as a valuable tool for CLD identification, potentially reducing cirrhosis development and clinical decompensation. This, in turn, may lead to a decrease in the economic impact on the healthcare system.
Appendix
Available only for authorised users
Literature
1.
go back to reference Younossi ZM (2019) Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol 70:531–544CrossRefPubMed Younossi ZM (2019) Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol 70:531–544CrossRefPubMed
2.
go back to reference Marcellin P, Kutala BK (2018) Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int 38:2–6CrossRefPubMed Marcellin P, Kutala BK (2018) Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int 38:2–6CrossRefPubMed
3.
go back to reference Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2095–2128CrossRefPubMedPubMedCentral Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2095–2128CrossRefPubMedPubMedCentral
4.
go back to reference Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70:151–171CrossRefPubMed Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70:151–171CrossRefPubMed
5.
go back to reference Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18:2650–2666CrossRefPubMed Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18:2650–2666CrossRefPubMed
6.
go back to reference Di Pascoli M, Ceranto E, De Nardi P, Donato D, Gatta A, Angeli P, Pontisso P (2017) Hospitalizations due to cirrhosis: clinical aspects in a large cohort of Italian patients and cost analysis report. Dig Dis 35:433–438CrossRefPubMed Di Pascoli M, Ceranto E, De Nardi P, Donato D, Gatta A, Angeli P, Pontisso P (2017) Hospitalizations due to cirrhosis: clinical aspects in a large cohort of Italian patients and cost analysis report. Dig Dis 35:433–438CrossRefPubMed
7.
go back to reference Asrani SK, Kouznetsova M, Ogola G, Taylor T, Masica A, Pope B, Trotter J, Kamath P, Kanwal F (2018) Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004–2013. Gastroenterology 155:719-729.e4CrossRefPubMed Asrani SK, Kouznetsova M, Ogola G, Taylor T, Masica A, Pope B, Trotter J, Kamath P, Kanwal F (2018) Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004–2013. Gastroenterology 155:719-729.e4CrossRefPubMed
8.
go back to reference Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL–lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399:61–116CrossRefPubMed Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL–lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399:61–116CrossRefPubMed
10.
go back to reference The Lancet Gastroenterology & Hepatology (2017) Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol 2:1CrossRef The Lancet Gastroenterology & Hepatology (2017) Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol 2:1CrossRef
11.
go back to reference Alter HJ, Chisari FV (2019) Is elimination of hepatitis B and C a pipe dream or reality? Gastroenterology 156:294–296CrossRefPubMed Alter HJ, Chisari FV (2019) Is elimination of hepatitis B and C a pipe dream or reality? Gastroenterology 156:294–296CrossRefPubMed
12.
go back to reference Williams R, Aspinall R, Bellis M et al (2014) Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384:1953–1997CrossRefPubMed Williams R, Aspinall R, Bellis M et al (2014) Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384:1953–1997CrossRefPubMed
13.
go back to reference Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A (2019) Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology 69:564–572CrossRefPubMed Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A (2019) Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology 69:564–572CrossRefPubMed
14.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRefPubMed Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRefPubMed
15.
go back to reference Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H (2010) Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51:1675–1682CrossRefPubMed Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H (2010) Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51:1675–1682CrossRefPubMed
16.
go back to reference Serra-Burriel M, Graupera I, Torán P et al (2019) Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol 71:1141–1151CrossRefPubMed Serra-Burriel M, Graupera I, Torán P et al (2019) Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol 71:1141–1151CrossRefPubMed
17.
go back to reference Younossi ZM, Henry L, Bush H, Mishra A (2018) Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 22:1–10CrossRefPubMed Younossi ZM, Henry L, Bush H, Mishra A (2018) Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 22:1–10CrossRefPubMed
18.
go back to reference Alina MA, Holly KVH, Lindsey RS, Jayant AT, Rozalina GM (2018) Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database. Hepatology 68:2230–2238CrossRef Alina MA, Holly KVH, Lindsey RS, Jayant AT, Rozalina GM (2018) Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database. Hepatology 68:2230–2238CrossRef
19.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G et al (2022) Baveno VII – renewing consensus in portal hypertension. J Hepatol 76:959–974CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G et al (2022) Baveno VII – renewing consensus in portal hypertension. J Hepatol 76:959–974CrossRefPubMed
20.
go back to reference Hofer BS, Simbrunner B, Hartl L et al (2023) Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int 43:2220–2231CrossRefPubMed Hofer BS, Simbrunner B, Hartl L et al (2023) Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int 43:2220–2231CrossRefPubMed
21.
go back to reference Villanueva C, Albillos A, Genescà J et al (2019) β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393:1597–1608CrossRefPubMed Villanueva C, Albillos A, Genescà J et al (2019) β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393:1597–1608CrossRefPubMed
22.
go back to reference Villanueva C, Torres F, Sarin SK et al (2022) Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 77:1014–1025CrossRefPubMed Villanueva C, Torres F, Sarin SK et al (2022) Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 77:1014–1025CrossRefPubMed
23.
go back to reference Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef
24.
go back to reference Härmälä S, O’Brien A, Parisinos CA, Direk K, Shallcross L, Hayward A (2019) Development and validation of a prediction model to estimate the risk of liver cirrhosis in primary care patients with abnormal liver blood test results: protocol for an electronic health record study in Clinical Practice Research Datalink. Diagnostic Progn Res 3:1–11CrossRef Härmälä S, O’Brien A, Parisinos CA, Direk K, Shallcross L, Hayward A (2019) Development and validation of a prediction model to estimate the risk of liver cirrhosis in primary care patients with abnormal liver blood test results: protocol for an electronic health record study in Clinical Practice Research Datalink. Diagnostic Progn Res 3:1–11CrossRef
25.
go back to reference Martini A, Ceranto E, Gatta A, Angeli P, Pontisso P (2017) Occult liver disease burden: analysis from a large general practitioners’ database. United Eur Gastroenterol J 5:982–986CrossRef Martini A, Ceranto E, Gatta A, Angeli P, Pontisso P (2017) Occult liver disease burden: analysis from a large general practitioners’ database. United Eur Gastroenterol J 5:982–986CrossRef
27.
go back to reference Pendino GM, Mariano A, Surace P et al (2005) Prevalence and etiology of altered liver tests: a population-based survey in a mediterranean town. Hepatology 41:1151–1159CrossRefPubMed Pendino GM, Mariano A, Surace P et al (2005) Prevalence and etiology of altered liver tests: a population-based survey in a mediterranean town. Hepatology 41:1151–1159CrossRefPubMed
28.
go back to reference Clark J (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960–967CrossRefPubMed Clark J (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960–967CrossRefPubMed
29.
go back to reference Petrides AS, DeFronzo RA (1989) Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev 5:691–709CrossRefPubMed Petrides AS, DeFronzo RA (1989) Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev 5:691–709CrossRefPubMed
30.
go back to reference Müller MJ, Pirlich M, Balks HJ, Selberg O (1994) Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences. Eur J Clin Chem Clin Biochem J Forum Eur Clin Chem Soc 32:749–758 Müller MJ, Pirlich M, Balks HJ, Selberg O (1994) Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences. Eur J Clin Chem Clin Biochem J Forum Eur Clin Chem Soc 32:749–758
31.
go back to reference Ajmera V, Cepin S, Tesfai K et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78:471–478CrossRefPubMed Ajmera V, Cepin S, Tesfai K et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78:471–478CrossRefPubMed
32.
go back to reference Lee WG, Wells CI, McCall JL, Murphy R, Plank LD (2019) Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis. Diabetes Metab Res Rev 35:e3157CrossRefPubMed Lee WG, Wells CI, McCall JL, Murphy R, Plank LD (2019) Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis. Diabetes Metab Res Rev 35:e3157CrossRefPubMed
33.
go back to reference Ginès P, Castera L, Lammert F et al (2022) Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 75:219–228CrossRefPubMed Ginès P, Castera L, Lammert F et al (2022) Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 75:219–228CrossRefPubMed
34.
go back to reference Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904CrossRefPubMed Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904CrossRefPubMed
Metadata
Title
Electronic sanitary database: a new potential tool to identify occult chronic liver disease in general population
Authors
Silvia Cagnin
Andrea Martini
Daniele Donato
Paolo Angeli
Patrizia Pontisso
Publication date
16-01-2024
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 3/2024
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-023-03507-1

Other articles of this Issue 3/2024

Internal and Emergency Medicine 3/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare